

## BIOPHYTIS will present at the Rodman & Renshaw 18<sup>th</sup> Annual Global Investment Conference In New York City, September 11-13, 2016

Romainville, September 5, 2016, 18H00 – BIOPHYTIS (Alternext Paris : ALBPS), a biotechnology society specialized in the development of drug candidates to treat ageing diseases, today announced that it will be featured as a presenting company at the Rodman & Renshaw 18<sup>th</sup> Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.

**Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with North-American investors. He explains:** *"Our participation in this conference expresses our willingness to strengthen our visibility towards the biotech and financial community in the USA. It is a key country for us both in terms of market as well financing and licensing opportunities."*

### **Rodman & Renshaw 18th Annual Global Investment Conference, September 11-13, 2016**

Day and time of the presentation: September 13, from 3.25pm to 3.50pm.

Location: Adams room (4<sup>th</sup> floor); Lotte New York Palace Hotel, New York City

The webcast replay will remain available for 90 days following the live presentation. To access the webcast, please visit: [www.rodmanevents.com](http://www.rodmanevents.com).

*If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link ([www.rodmanevents.com](http://www.rodmanevents.com)) to register for the BIOPHYTIS conference.*

\*\*\*\*

### **About BIOPHYTIS:**

Biophytis SA ([www.biophytis.com](http://www.biophytis.com)), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry agerelated macular

degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS ; ISIN: FR0012816825).

For more information: <http://www.biophytis.com>

**ALBPS**  
**LISTED**  
**ALTERNEXT**



### Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on BIOPHYTIS' website ([www.biophytis.com](http://www.biophytis.com)).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.

**BIOPHYTIS**  
**Stanislas VEILLET**  
CEO  
contact@biophytis.com  
Tel : +33 (0) 1 41 83 66 00

**Milestones**  
**Presse & Relations Investisseurs**  
**Bruno ARABIAN**  
barabian@milestones.fr  
Tel : +33 (0) 1 83 62 34 84  
Mob : +33 (0) 6 87 88 47 26

**LifeSci Advisors**  
**Chris MAGGOS**  
Managing Director, Europe  
chris@lifesciadvisors.com  
Tel : +41 79 367 6254

**Citigate Dewe Rogerson**  
**Presse internationale**  
**Laurence BAULT/Antoine DENRY**  
[Laurence.bault@citiagte.fr](mailto:Laurence.bault@citiagte.fr)/[adenry@citigate.fr](mailto:adenry@citigate.fr)  
Tel : +33 (0)1 53 32 84 78  
Mob : +33(0)6 64 12 53 61